GT Biopharma (GTBP) Common Equity (2010 - 2026)

GT Biopharma (GTBP) has reported Common Equity for 17 consecutive years, with $7.6 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Common Equity rose 873.47% year-over-year to $7.6 million in Q1 2026; TTM through Mar 2026 was $7.6 million, a 873.47% increase from a year earlier, with the FY2025 full-year figure at $5.8 million, up 446.53% from the prior year.
• Common Equity was $7.6 million for Q1 2026 at GT Biopharma, up from $5.8 million in the prior quarter.
• Over five years, Common Equity peaked at $17.8 million in Q1 2022 and troughed at -$25.9 million in Q2 2025.
• A 5-year average of $6.1 million and a median of $7.5 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity tumbled 569.77% in 2025 and soared 873.47% in 2026, its largest moves.
• Over 5 years, Common Equity stood at $11.7 million in 2022, then slumped by 36.29% to $7.5 million in 2023, then plunged by 122.34% to -$1.7 million in 2024, then jumped by 446.53% to $5.8 million in 2025, then jumped by 30.98% to $7.6 million in 2026.
• The last three Common Equity figures came in at $7.6 million (Q1 2026), $5.8 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.